3  ANKRD26

3.1 ANKRD26-RT

3.1.1 Eight patients with ANKRD26-RT from five families. Wahlster et al. (2025)

3.1.2 Risk of Hematologic Neoplasms

  • AML and MDS are the most commonly described, though there are some reports of lymphoid malignancies
  • a single case report of a patient with a 5’UTR mutation developing multiple myeloma.
  • An extended case series of 118 subjects with confirmed or highly probable ANKRD26-RT revealed an 8% incidence of myeloid malignancy (AML, MDS, and chronic myeloid leukemia (CML)). Noris et al. (2011)
  • An estimated 24-fold increase in acute leukemia incidence alone is reported compared to the general population in this study

3.1.3 Risk of Thrombosis

3.2 WAC::ANKRD26 fusion

  • Familial thrombocytopenia secondary to germline WAC::ANKRD26 fusion shares key clinical and biological features with classical thrombocytopenia 2(THC2), including thrombocytopenia and hyperactive ERK signaling, but represents a genetically distinct alteration characterized by aberrant overexpression of N-terminally truncated ANKRD26 (exons 11-34) under the WAC promoter. Wahlster et al. (2021)